当前位置: 首页 > 期刊 > 《中国医学创新》 > 2023年第11期
编号:178541
成人IMN患者PLA2R抗体诊疗价值研究近况
http://www.100md.com 2023年6月28日 中国医学创新 2023年第11期
表位,滴度,结构域
     张莹莹 郭彦聪

    【摘要】 特发性膜性肾病(IMN)是由抗体介导的一种肾脏特异性疾病,经皮肾穿刺活检术是确诊IMN的金标准,目前认为M型磷脂酶A2受体(PLA2R)是IMN患者足细胞上的特异性靶抗原,血清中可检测出相应的抗体,这一发现彻底改变了既往膜性肾病(MN)的诊断和治疗方法。本综述将从血清抗磷脂酶A2受体抗体(PLA2R-Ab)对IMN的诊断、治疗及预后的临床意义方面进行阐述,并探讨目前尚未解决的问题。

    【关键词】 特发性膜性肾病 磷脂酶A2受体 1型血小板反应蛋白7A域 利妥昔单抗

    Recent Research on the Diagnostic and Therapeutic Value of PLA2R Antibody in Adult Patients with IMN/ZHANG Yingying, GUO Yancong. //Medical Innovation of China, 2023, 20(11): -178

    [Abstract] Idiopathic membranous nephropathy (IMN) is a kind of kidney-specific disease mediated by antibodies. Percutaneous renal biopsy is the gold standard for the diagnosis of IMN. At present, it is considered that M-type phospholipase A2 receptor (PLA2R) is a specific target antigen on podocytes of patients with IMN, and the corresponding antibodies can be detected in serum. This discovery has completely changed the diagnosis and treatment methods of previous membranous nephropathy (MN). This review will expound the clinical significance of serum anti-phospholipase A2 receptor antibody (PLA2R-Ab) in the diagnosis, treatment and prognosis of IMN ......

您现在查看是摘要页,全文长 18085 字符